

17 Apr 2022 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: GSK pursues M&A to boost pipeline; US decision affects Alzheimer's candidates; Boehringer Ingelheim's hopes for Jardiance; Japan rebuilds generic supplies; and a look at key upcoming trial readouts.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 15 April 2022, including: [GlaxoSmithKline plc](#) pursues M&A to boost pipeline; US decision affects Alzheimer's candidates; [Boehringer Ingelheim GmbH](#)'s hopes for Jardiance; Japan looks to rebuild generic supplies; and a look at key upcoming trial readouts.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Another New Home For Momelotinib As GSK Buys Sierra](#)" - Scrip, 13 Apr, 2022.)

(Also see "[Biogen's Aduhelm Competitors Boosted By Final CMS Coverage Decision](#)" - Scrip, 9 Apr, 2022.)

(Also see "[Boehringer Pharma Chief Confident Of Continued Success For Jardiance](#)" - Scrip, 12 Apr, 2022.)

(Also see "[A Year's Struggle: How Japan Is Recovering Damaged Generic Supplies After Quality](#)"

[Violations](#)" - Scrip, 12 Apr, 2022.)

(Also see "[Four Major Clinical Trial Readouts To Watch Out For In Q2](#)" - Scrip, 12 Apr, 2022.)

[Click here to explore this interactive content online](#) ✨